Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is making strides in neurological health through a two-pronged strategy that includes an investigational therapy for multiple sclerosis (MS) and a dietary supplement aimed at mitigating the effects of alcohol. The company is developing Lucid-MS, a patented new chemical entity designed to target PAD2, an enzyme associated with myelin degradation. Unlike traditional MS treatments that primarily modulate the immune system, Lucid-MS aims to protect and potentially restore the myelin sheath, addressing the underlying mechanism of the disease. This approach could represent a paradigm shift in MS treatment, offering hope for disease modification rather than just symptomatic relief.
Quantum BioPharma has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 trial of Lucid-MS. The company is also supporting the development through an imaging collaboration with Massachusetts General Hospital, which could help in assessing the drug's effect on myelin integrity. This collaboration underscores the company's commitment to rigorous scientific evaluation and its potential to bring a first-in-class therapy to patients.
In parallel, Quantum BioPharma is advancing unbuzzd, a proprietary dietary supplement designed to support alcohol metabolism and reduce acute intoxication and hangover effects. The company cites results from a randomized, placebo-controlled clinical trial that demonstrated the product's efficacy. unbuzzd is being commercialized through a spin-out company, Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI (as of March 31, 2026) and is entitled to royalty payments of 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. This arrangement allows Quantum BioPharma to benefit from the commercial success of unbuzzd while retaining the rights to develop pharmaceutical-grade formulations for medical use.
The dual focus on both a disease-modifying therapy for MS and a consumer health product for alcohol misuse positions Quantum BioPharma to address significant unmet needs. MS affects approximately 2.8 million people worldwide, and current treatments often have limited efficacy in preventing disability progression. By targeting myelin repair, Lucid-MS could offer a new option for patients. Meanwhile, alcohol misuse is a global public health concern, and products like unbuzzd could provide a harm-reduction tool.
Quantum BioPharma's pipeline includes drug candidates in different stages of development for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company's strategic approach, combining innovative science with commercial partnerships, may enhance its ability to bring these therapies to market. Investors and stakeholders are watching closely as the company progresses with its clinical and regulatory milestones.
For more information about Quantum BioPharma and its latest news, visit the company's newsroom at https://ibn.fm/QNTM.
